查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612120

同種異體細胞治療市場：按類型、應用和最終用途 - 2025-2030 年全球預測

Allogeneic Cell Therapy Market by Type, Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年同種異體細胞治療市值為20.4億美元，預計2024年將達23.1億美元，複合年成長率為13.90%，到2030年將達到50.8億美元。

同種異體細胞療法涉及使用來自捐贈者的細胞來治療各種疾病和病症，並且與利用患者自身細胞的自體細胞療法不同。這種需求源於隨時獲得治療方法和標準化細胞產品的可能性，以解決傳統方法通常無法治療的癌症和遺傳性疾病等嚴重。臨床上，該療法已應用於血液學、腫瘤學、心臟病學和再生醫學，其中移植和組織再生是主要的最終應用領域。主要成長動力包括慢性病盛行率上升、研發投資增加、細胞技術進步。機會包括擴大罕見疾病的應用、改善商業規模的製造以及製定強力的法規結構以促進市場准入。抓住這些機會的研究包括促進生物製藥公司、研究機構和政府機構之間的合作，以簡化開發和監管流程。然而，也存在重大限制，例如治療成本高、製造複雜性、免疫排斥的可能性以及圍繞細胞採購和操作的倫理問題，這些可能會阻礙市場成長。挑戰包括監管障礙、嚴格的品管措施以及確保移植的適用性。儘管如此，在基因編輯技術、增強冷凍保存技術和抑制免疫反應的通用供體細胞株等領域仍存在創新機會。此外，開發更具成本效益和可擴展的製造解決方案可以顯著提高市場滲透率。該市場的特點是技術進步迅速、競爭激烈、高度關注臨床療效和安全性。整體而言，市場成功之路需要策略創新、協作以及積極主動的方法來克服道德和監管挑戰。

主要市場統計
基準年[2023] 20.4億美元
預計年份 [2024] 23.1億美元
預測年份 [2030] 50.8億美元
複合年成長率（%） 13.90%

市場動態：針對快速發展的同種異體細胞治療市場揭示的關鍵市場見解

同種異體細胞治療市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症、自體免疫疾病和心血管疾病的增加
    • 有利的政府政策和細胞治療研究經費的增加
  • 市場限制因素
    • 同種異體細胞療法的開發和管理的複雜法規環境
  • 市場機會
    • 個性化同種異體細胞治療解決方案的開發
    • 開拓神經退化性疾病和心臟疾病的新治療方法
  • 市場挑戰
    • 免疫排斥和相容性問題

波特五力：駕馭同種異體細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解異體細胞治療市場的外部影響

外部宏觀環境因素在塑造同種異體細胞治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解同種異體細胞治療市場的競爭格局

同種異體細胞治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣同種異體細胞治療市場供應商績效評估

FPNV定位矩陣是評估同種異體細胞治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了同種異體細胞治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，同種異體細胞治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症、自體免疫疾病和心血管疾病的發生率增加
      • 有利的政府政策和增加細胞治療方法研究資金
    • 抑制因素
      • 同種異體細胞療法開發和管理的複雜法規環境
    • 機會
      • 開發個人化同種異體細胞治療解決方案
      • 探索神經退化性疾病疾病和心臟病的新治療方法
    • 任務
      • 免疫排斥和相容性問題
  • 市場區隔分析
    • 類型：由於發炎和免疫調節特性，間質幹細胞療法的採用增加
    • 應用：徹底改變同種異體細胞療法在器官移植治療和改善中的作用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章同種異體細胞治療市場：依類型

  • 嵌合體抗原受體T細胞療法
  • 造血幹細胞移植
  • 誘導性多功能幹細胞治療
  • 間質幹細胞治療

第7章同種異體細胞治療市場：依應用分類

  • 血液疾病
  • 腫瘤學
  • 再生醫學
  • 固態器官移植

第8章同種異體細胞治療市場：依最終用途

  • 生物技術和製藥公司
  • 醫院/診所
  • 調查機構

第9章美洲同種異體細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太同種異體細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲同種異體細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Getinge 與 Sellev 之間的策略合作夥伴關係將徹底改變製造業。
    • 開創性協議將促進全球獲得 StemCyte 突破性的臍帶血衍生細胞療法
    • FDA核准Gamida Cell 的 Omisirge 療法作為血癌治療的突破性進展
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals
Product Code: MRR-CA100284D019

The Allogeneic Cell Therapy Market was valued at USD 2.04 billion in 2023, expected to reach USD 2.31 billion in 2024, and is projected to grow at a CAGR of 13.90%, to USD 5.08 billion by 2030.

Allogeneic cell therapy involves the use of cells from a donor to treat various diseases and medical conditions, making it distinct from autologous therapies that utilize a patient's own cells. Its necessity stems from the potential to provide immediate availability of treatment and standardized cell products, addressing severe diseases, such as cancers and genetic disorders, which are often untreatable by conventional means. Clinically, this therapy has found applications in hematology, oncology, cardiology, and regenerative medicine, with transplant and tissue regeneration being primary end-use areas. Key growth drivers include rising prevalence of chronic diseases, increasing investments in research and development, and advances in cell-based technologies. Opportunities lie in expanding applications to rare diseases, commercial-scale manufacturing improvements, and developing robust regulatory frameworks that expedite market access. Recommendations for seizing these opportunities include fostering collaborations between biopharmaceutical companies, research institutes, and governmental bodies to streamline development and regulatory processes. However, substantial limitations exist, such as the high cost of therapy, complexity of production, potential for immune rejection, and ethical concerns around cell sourcing and manipulation, which could impede market growth. Challenges include regulatory hurdles, stringent quality control measures, and ensuring compatibility in transplantation. Still, innovation potentials abound in areas such as gene-editing technologies, enhanced cryopreservation techniques, and universal donor cell lines to reduce immune responses. Furthermore, the development of more cost-effective and scalable manufacturing solutions can significantly boost market penetration. The market is characterized by rapid technological advancements, competitive tension, and a strong focus on clinical efficacy and safety. Overall, the path to market success requires strategic innovations, collaboration, and a proactive approach to overcoming ethical and regulatory challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.31 billion
Forecast Year [2030] USD 5.08 billion
CAGR (%) 13.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
    • Favorable government policies and increased funding for research in cell-based therapies
  • Market Restraints
    • Complex regulatory environment for development and administration of allogeneic cell therapies
  • Market Opportunities
    • Development of personalized allogeneic cell therapy solutions
    • Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
  • Market Challenges
    • Immune rejection and compatibility issues

Porter's Five Forces: A Strategic Tool for Navigating the Allogeneic Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allogeneic Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allogeneic Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allogeneic Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allogeneic Cell Therapy Market

A detailed market share analysis in the Allogeneic Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allogeneic Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allogeneic Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allogeneic Cell Therapy Market

A strategic analysis of the Allogeneic Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chimeric Antigen Receptor T Cell Therapy, Hematopoietic Stem Cell Transplantation, Induced Pluripotent Stem Cell Therapy, and Mesenchymal Stem Cell Therapy.
  • Based on Application, market is studied across Hematological Disorders, Oncology, Regenerative Medicine, and Solid Organ Transplantation.
  • Based on End-Use, market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
      • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
      • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Immune rejection and compatibility issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
    • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allogeneic Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor T Cell Therapy
  • 6.3. Hematopoietic Stem Cell Transplantation
  • 6.4. Induced Pluripotent Stem Cell Therapy
  • 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Hematological Disorders
  • 7.3. Oncology
  • 7.4. Regenerative Medicine
  • 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
    • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
    • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. AlloSource
  • 3. Anterogen.Co., Ltd.
  • 4. Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • 5. Athersys Inc.
  • 6. Biorestorative Therapies Inc.
  • 7. Biosolution Co., Ltd.
  • 8. Bloodworks Northwest
  • 9. Brainstorm Cell Limited
  • 10. Caribou Biosciences
  • 11. Fate Therapeutics
  • 12. Gamida Cell
  • 13. Hope Biosciences
  • 14. JCR Pharmaceuticals Co., Ltd.
  • 15. Mallinckrodt Pharmaceuticals
  • 16. MEDIPOST Co., Ltd.
  • 17. Mesoblast Ltd.
  • 18. NuVasive Inc. by Globus Medical
  • 19. RTI Surgical
  • 20. Smith+Nephew PLC
  • 21. Stempeutics Research Pvt. Ltd.
  • 22. Sumitomo Pharma Co., Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Tego Science Inc.
  • 25. ViaCyte Inc. by Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023